Navigation Links
Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
Date:5/26/2010

.S. alone.

Recently published data also indicates that physicians only co-prescribe GI protective agents 27 percent of the time.  In addition, historical data has shown that, by the third prescription, over 60 percent of patients stop taking their prescribed GI co-therapy.  

About Horizon Pharma

Horizon Pharma, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and chronic inflammation.   Horizon's product portfolio includes innovative therapies in early- and late-stage development that are designed to improve the efficacy, safety and quality of life for patients with chronic pain and inflammation.   Horizon's most advanced product is LODOTRA, a circadian cytokine modulator (CCM) for the treatment of the signs and symptoms of rheumatoid arthritis (RA), which has received a recommendation for granting of a national marketing authorization in certain Member States of the European Union.  L ODOTRA is already launched in Germany.   The company's lead development stage product is DUEXA, a novel, proprietary fixed-dose tablet combining one of the most prescribed NSAIDs in the world, ibuprofen, with a high dose of the most potent H2 antagonist, famotidine, in a single pill.   In two Phase 3 clinical studies (REDUCE-1 and REDUCE-2), DUEXA was shown to significantly reduce the incidence of NSAID-induced upper gastrointestinal (GI) ulcers in patients with mild-to-moderate pain and arthritis.   The Company is financed by leading life-science investors Atlas Venture, Deutsche Bank AG, London, Essex Woodlands Healthcare Ventures, FirstMark Capital, Global Life Science Ventures, NGN Capital, Scale Ventures, Sutter Hill Ventures and TVM Capital.

For more info
'/>"/>

SOURCE Horizon Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
2. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
3. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
4. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
5. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
6. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
7. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
8. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
9. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
11. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... NEW YORK , April 21, 2015 ... Summary Sepsis is a life-threatening complication arising ... to the infection damages its own tissues and organs. ... common among children <1 year of age, ... Clinic, 2014). Global estimates for the year 2013 showed ...
(Date:4/21/2015)... SAN DIEGO , 21. April 2015 ... Software für die quantitative Analyse des Hirnvolumens ... AG, einem weltweiten Pharmaunternehmen, bekannt geben zu ... des leistungsstarken NeuroQuant-Quantifizierungsreports des Hirnvolumens zusammenarbeiten, der ... von Hirnvolumen in Patienten mit multipler Sklerose ...
(Date:4/21/2015)... InfuSystem Holdings, Inc. (NYSE MKT: INFU), a ... for the healthcare industry in the United ... announces today that it has closed the acquisition by ... Ciscura Holding Company, Inc., and its subsidiaries.  Ciscura, based ... privately-held Southeastern regional provider of ambulatory infusion pumps and ...
Breaking Medicine Technology:EpiCast Report: Sepsis - Epidemiology Forecast to 2023 2EpiCast Report: Sepsis - Epidemiology Forecast to 2023 3CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 2InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 3InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 4
... Dec. 21, 2011  Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE)("Ampio" or ... uses for previously approved drugs and new molecular entities ... agreements with accredited investors to sell an aggregate approximately ... $0.0001 per share (the "Shares"), at a price per ...
... Dec. 21, 2011 At a ceremony coinciding with ... Johnson,s public revelation that he had acquired HIV, the ... acknowledged Waters Corporation (NYSE: WAT ) for ... liquid chromatograph/mass spectrometer that will be used to build ...
Cached Medicine Technology:Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million 2Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million 3Waters Gifts Research Equipment to University at Buffalo to Combat HIV/AIDS 2Waters Gifts Research Equipment to University at Buffalo to Combat HIV/AIDS 3Waters Gifts Research Equipment to University at Buffalo to Combat HIV/AIDS 4
(Date:4/21/2015)... Top medical tourism firm, VisitandCare.com, is ... ongoing commitment to providing superior patient experiences. Ojas ... with the best possible experience for a comprehensive range ... , Executives at Ojas Aesthetic Clinic persistently assert that, ... nothing about you, without you — through transparent engagement ...
(Date:4/21/2015)... Angelo’s FabriClean has recently announced that the company ... avail the area rug cleaning services. Area rug cleaning ... equipments, making use of the quick drying technique to ... pressure steam extraction to clean even the most stubborn ... made with delicate fabric. , “Good maintenance and ...
(Date:4/21/2015)... Somerset, NJ & New York, NY (PRWEB) April ... the leading global provider of advanced delivery technologies ... health products, today announced the launch of ADVASEPT™ ... the safe and efficient delivery of injectable medications. ... syringe, combining a safe, convenient and functional container ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 QuickMedical, ... equipment and supplies, now represents Schiller America's ... Monitors, ECGs, Stress Tests, and Vital Signs Monitors, ... in Switzerland, is a global leader in the ... products are developed in close cooperation with the ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 21, 2015 ... Global Sodium Citrate Industry is a professional and ... global Sodium Citrate Market with a ... companies included in the sodium citrate market research ... Acid Chemicals, Natural Biological, Cofco Biochemical, Capchem, Lianyungang ...
Breaking Medicine News(10 mins):Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3
... phase of the illness, study says , , WEDNESDAY, Sept. 12 ... the manic phase of bipolar disorder, and works faster than ... a new study has found. , "One of the problems ... have this long period before they start to work," explained ...
... Chance to Help Make a Difference & Join ... N.C., Sept. 12 This fall, Pink is the color,of ... its,14th anniversary in the battle against Breast Cancer September 20 ... to save lives by,purchasing a new 25% Pink Savings Card. ...
... CDH plans continue to grow in popularity among ... Employees who fear high,out-of-pocket costs aren,t blocking the ... and employers take advantage of,money-saving options as healthcare ... Consulting Worldwide, the global human capital consulting,organization of ...
... prevailing issue in the United States, with millions of ... that Pycnogenol, (pic-noj-en-all), an antioxidant plant extract from the ... in children. The study shows Pycnogenol balances stress hormones, ... of ADHD. , The findings, to be published ...
... the days of Hippocrates, people have known that certain ... researchers have learned that these cyclic recurrences of disease, ... In order to accurately predict when outbreaks of disease ... Elena Naumova, PhD, associate professor in the Department of ...
... LOS GATOS, Calif., Sept. 12 Death may be the ... about. It is usually looked,upon as something to fear -- ... Darlyne intend to tear down the walls. "Triumph" is ... Philip,and Darlyne clarified and expressed their feelings about Darlyne,s,impending death ...
Cached Medicine News:Health News:Tamoxifen Helps Treat Bipolar Disorder 2Health News:Tamoxifen Helps Treat Bipolar Disorder 3Health News:Photo: Tanger Outlet Center Shoppers Nationwide can Choose Pink to Fight Breast Cancer 2Health News:National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline 2Health News:National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline 3Health News:National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline 4Health News:National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline 5Health News:National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline 6Health News:National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline 7Health News:National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline 8Health News:New study: Pine bark extract reduces ADHD symptoms in children 2Health News:Mathematics might save you a trip to the ER 2Health News:'Triumph' -- Traveling Towards Death: Preparing for a New Life 2
Chin Implants are used for cosmetic augmentation, repairing trauma related injuries and genetic deficiencies. They are inserted through an incision in the mouth below the incisor teeth or through an ...
... The IEC CL40 and FL40 Centrifuge ... safety and versatility to increase your ... a broad array of rotors and ... and microplate applications, the IEC CL40 ...
... CL40 and FL40 Centrifuge Series from ... versatility to increase your productivity in ... array of rotors and accessories for ... applications, the IEC CL40 and FL40 ...
... IEC CL31 Multispeed Series offers unsurpassed ... quiet, compact, 1.2 liter benchtop centrifuge. ... and accessories and high-speed centrifugation capabilities, ... everything you need to meet a ...
Medicine Products: